Industry Presentations
LUGPA Crossfire Series - UTUC
Presentations
Practical Considerations in Low-grade UTUC Care
Speakers: Marc A. Bjurlin, DO, MScDaniel Lee, MD, MSNeal D. Shore, MD, FACS, Medical Director, CPI Duration: 60 minutes
Presented on: November 28, 2023
*This session is not eligible for AMA PRA Category 1 CreditsTM
Kidney-Sparing Approaches in UTUC: A Risk-Based Approach to Care
Speakers: Neal D. Shore, MD, FACSRian Dickstein, MD, FACS, Clinical Assistant Professor, Department of Surgery Duration: 60 minutes
Presented on: August 31, 2023
*This session is not eligible for AMA PRA Category 1 CreditsTM
Speakers
Marc A. Bjurlin, DO, MSc
Marc A. Bjurlin, DO, MSc
Daniel Lee, MD, MS
Daniel Lee, MD, MS
Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS
Medical Director, CPI
Neal Shore, MD, is the Medical Director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 400 clinical trials, focusing on GU Oncology indications. He is the Chief Medical Officer, Surgery/Urology, for GenesisCare,US. Dr. Shore serves on the SITC Guidelines Committee for Bladder Cancer and the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the Chair of the LUGPA Education Committee. Dr. Shore is on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, World Journal of Urology, and serves as Editor for Everyday Urology-Oncology. Also, he’s a Fellow of the American College of Surgeons.Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 175 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.Session Appearances
Moving Beyond ADT Alone: The Rationale for Early Intensification in mHSPC
The Evolution of the Modern Care Team with New mHSPC Treatment Options
Kidney-Sparing Approaches in UTUC: A Risk-Based Approach to Care
Optimizing Decision Making for Patients with mHSPC: Case-Based Review of Doublets vs Triplets
Rian Dickstein, MD, FACS
Rian Dickstein, MD, FACS
Clinical Assistant Professor, Department of Surgery